Immunotherapy in genitourinary malignancies

3Citations
Citations of this article
53Readers
Mendeley users who have this article in their library.

Abstract

Most cancer patients are treated with some combination of surgery, radiation, and chemotherapy. Despite recent advances in local therapy with curative intent, chemotherapeutic treatments for metastatic disease often remain unsatisfying due to severe side effects and incomplete long-term remission. Therefore, the evaluation of novel therapeutic options is of great interest. Conventional, along with newer treatment strategies target the immune system that suppresses genitourinary (GU) malignancies. Metastatic renal cell carcinoma and non-muscle-invasive bladder caner represent the most immune-responsive types of all human cancer. This review examines the rationale and emerging evidence supporting the anticancer activity of immunotherapy, against GU malignancies.

Cite

CITATION STYLE

APA

Wattenberg, M. M., Fong, L., Madan, R. A., & Gulley, J. L. (2016, October 1). Immunotherapy in genitourinary malignancies. Current Opinion in Urology. Lippincott Williams and Wilkins. https://doi.org/10.1097/MOU.0000000000000331

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free